TY - JOUR
T1 - Preadmission Diuretic Use and Mortality in Patients Hospitalized With Hyponatremia
T2 - A Propensity Score-Matched Cohort Study
AU - Holland-Bill, Louise
AU - Christiansen, Christian F
AU - Ulrichsen, Sinna P
AU - Ring, Troels
AU - Lunde Jørgensen, Jens O
AU - Sørensen, Henrik T
PY - 2019/1
Y1 - 2019/1
N2 - BACKGROUND:: Hyponatremia is associated with increased mortality and is frequently induced by diuretic use. It is uncertain whether diuretic use is linked to mortality risk in patients with hyponatremia. STUDY QUESTION:: To measure the prognostic impact of diuretic use on 30-day mortality among patients hospitalized with hyponatremia. STUDY DESIGN:: Using population-based registries, we identified all patients with a serum sodium measurement <135 mmol/L within 24 hours after acute hospital admission in western Denmark from 2006 to 2012 (cumulative population of 2.2 million). We categorized patients as current diuretic users (new and long-term), former users or nonusers, and followed them until death, migration or up to 30 days which ever came first. MEASURES AND OUTCOMES:: Thirty-day cumulative mortality and relative risk with 95% confidence interval (CI) controlled for demographics, previous morbidity, renal function, and co-medications. Calculations were also divided by the diuretic type and were repeated after propensity score matching. RESULTS:: Thirty-day mortality was 11.4% among current diuretic users (n = 14,635) compared with 6.2% among nonusers, yielding an adjusted relative risk of 1.4 (95% CI, 1.2–1.5). New users were at higher risk (1.7, 95% CI, 1.5–2.0) than long-term users (1.3, 95% CI, 1.2–1.4). In particular, the use of loop diuretics (1.6, 95% CI, 1.4–1.8), potassium-sparing diuretics (1.6, 95% CI, 1.2–2.2), and diuretic polytherapy (1.5, 95% CI, 1.3–1.7) were associated with increased risk, whereas thiazide use was not (1.0, 95% CI, 0.9–1.2). Propensity score–matched analyses confirmed the results. CONCLUSIONS:: Diuretic use except from thiazides, and particularly if newly initiated, is a negative prognostic factor in patients admitted with hyponatremia.
AB - BACKGROUND:: Hyponatremia is associated with increased mortality and is frequently induced by diuretic use. It is uncertain whether diuretic use is linked to mortality risk in patients with hyponatremia. STUDY QUESTION:: To measure the prognostic impact of diuretic use on 30-day mortality among patients hospitalized with hyponatremia. STUDY DESIGN:: Using population-based registries, we identified all patients with a serum sodium measurement <135 mmol/L within 24 hours after acute hospital admission in western Denmark from 2006 to 2012 (cumulative population of 2.2 million). We categorized patients as current diuretic users (new and long-term), former users or nonusers, and followed them until death, migration or up to 30 days which ever came first. MEASURES AND OUTCOMES:: Thirty-day cumulative mortality and relative risk with 95% confidence interval (CI) controlled for demographics, previous morbidity, renal function, and co-medications. Calculations were also divided by the diuretic type and were repeated after propensity score matching. RESULTS:: Thirty-day mortality was 11.4% among current diuretic users (n = 14,635) compared with 6.2% among nonusers, yielding an adjusted relative risk of 1.4 (95% CI, 1.2–1.5). New users were at higher risk (1.7, 95% CI, 1.5–2.0) than long-term users (1.3, 95% CI, 1.2–1.4). In particular, the use of loop diuretics (1.6, 95% CI, 1.4–1.8), potassium-sparing diuretics (1.6, 95% CI, 1.2–2.2), and diuretic polytherapy (1.5, 95% CI, 1.3–1.7) were associated with increased risk, whereas thiazide use was not (1.0, 95% CI, 0.9–1.2). Propensity score–matched analyses confirmed the results. CONCLUSIONS:: Diuretic use except from thiazides, and particularly if newly initiated, is a negative prognostic factor in patients admitted with hyponatremia.
U2 - 10.1097/MJT.0000000000000544
DO - 10.1097/MJT.0000000000000544
M3 - Journal article
C2 - 28005557
SN - 1075-2765
VL - 26
SP - e79-e91
JO - American Journal of Therapeutics
JF - American Journal of Therapeutics
IS - 1
ER -